News
Keep up-to-date on drug shortages, new ANDAs and NDAs, Nexus Milestones and more.Our mission drives everything we do. We develop, advance and deploy life-saving, critical-need drugs to institutions that depend on them every day.
Nexus Pharmaceuticals Announces Launch of Succinylcholine Chloride Injection, USP
Nexus Pharmaceuticals announced the launch of Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN™¥.
Nexus Pharmaceuticals Receives FDA Approval for Potassium Chloride in Water for Injection
Nexus Pharmaceuticals announced today that it has received U.S. Food and Drug Administration (FDA) approval for Potassium Chloride in Water for Injection in 10mEq/100mL, 10mEq/50mL, 20mEq/100mL, 40mEq/100mL and 20mEq/50mL Single-Dose IV bags.
Nexus Pharmaceuticals Announces Verbal to Occupy Authorization
Nexus Pharmaceuticals, Inc. is pleased to announce that it has received authorization to occupy its new pharmaceutical manufacturing facility from the Village of Pleasant Prairie, Wisconsin.
Nexus Pharmaceuticals Discusses COVID-19 Response in BioForward Webinar
Nexus Pharmaceuticals Chief Strategy Officer, Omair Ahmed, joined nine BioForward member organizations in a discussion regarding the Wisconsin biohealth industry’s response to the COVID-19 pandemic.
Nexus Pharmaceuticals sets month for $100M plant opening, preps drug for treating Covid patients
Nexus Pharmaceuticals Inc. plans to complete its nearly $100 million Pleasant Prairie sterile injectables plant in April 2021 and a company executive said it will help address the United States’ reliance on foreign pharmaceutical suppliers magnified by the Covid-19 pandemic.
Nexus Pharmaceuticals Announces Diversity Certification
Nexus Pharmaceuticals is pleased to announce their continuous certification as a Minority Business Enterprise (MBE) and a Women’s Business Enterprise (WBE).
Nexus Pharmaceuticals Announces Great Place to Work® Certification
Nexus Pharmaceuticals is pleased to announce its certification as a Great Place to Work by the Great Place to Work® Institute for a second consecutive year.
Nexus Pharmaceuticals Receives FDA Approval for Succinylcholine Chloride Injection, USP
Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN™¥.
Nexus Pharmaceuticals Named One of the 2020 Best Workplaces in Chicago by Great Place to Work®
Nexus Pharmaceuticals is pleased to announce its certification as a Great Place to Work. Ninety percent of Nexus employees saying the company is a great place to work.
Nexus Pharmaceuticals, Inc. Announces Approval of Emerphed™ (ephedrine sulfate) Injection, the First and Only FDA-approved, Ready-to-Use Ephedrine Injection (50 mg/10 mL vial)
Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for its New Drug Application (NDA) Emerphed, the first and only premixed ephedrine in a ready-to-use 50 mg/10 mL vial.
Nexus Pharmaceuticals Official Response: Supply Chain Reassurance Amid COVID-19 Outbreak
In light of the recent global outbreak of COVID-19 (Novel Coronavirus), Nexus Pharmaceuticals would like to take the opportunity to provide its partners reassurance on Nexus Pharmaceuticals products’ sourcing and manufacturing.
Nexus Pharmaceuticals Announces Great Places to Work® Certification
Nexus Pharmaceuticals is pleased to announce its certification as a Great Place to Work. Ninety percent of Nexus employees say the company is a great place to work.
Nexus Pharmaceuticals Ranks #574 in Inc. 5000 Fastest-Growing Private Companies in America
Nexus Pharmaceuticals is pleased to announce the company has ranked #574 in Inc. 5000’s Fastest-Growing Private Companies in America in 2019.
Nexus Pharmaceuticals to Build Industry-Leading Sterile Injectable Manufacturing Facility in Pleasant Prairie, Wisconsin
Nexus Pharmaceuticals Inc., a woman-owned, privately held, US-based healthcare company, announced today an agreement with the village of Pleasant Prairie, Wisconsin to build an industry-leading sterile injectable manufacturing facility.
Nexus Pharmaceuticals Receives FDA Approval for Prochlorperazine Edisylate Injection, USP
Lincolnshire, Ill., February 21, 2019 — Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for Prochlorperazine Edisylate Injection, USP in 10mg/2mL vial. “The launch further expands our generic injectable portfolio...
Nexus Pharmaceuticals Announces FDA Approval of Dicyclomine HCl Injection, USP
Lincolnshire, Ill., February 14, 2019 — Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for Dicyclomine Hydrochloride (HCl) Injection, USP in 20mg/2mL vial, the generic equivalent to Bentyl®. Dicyclomine HCl, USP,...
Nexus Pharmaceuticals Announces FDA Approval of Busulfan Injection
Lincolnshire, Ill., January 16, 2019 — Nexus Pharmaceuticals Inc. announced today the U.S. Food and Drug Administration (FDA) approval of Busulfan Injection, the company’s AP-rated therapeutic equivalent for Busulfex® 60 mg/10 mL (6 mg/1 mL). “The FDA approval of...
Nexus Pharmaceuticals Receives FDA Approval for Arsenic Trioxide Injection in 10mg per 10mL Vial
Vernon Hills, IL., Nov. 15th, 2018 – Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals’ Arsenic Trioxide Injection is available as 10mg per 10mL vial for injection. The product...
Nexus Pharmaceuticals Receives FDA Approval for Procainamide HCL Injection
Vernon Hills, Ill., Oct. 19, 2017 — Nexus Pharmaceuticals announced today the immediate availability in the United States of Procainamide HCL Injection, USP. Nexus Pharmaceuticals’ Procainamide HCL Injection, USP is available as a multi dose vial containing 1,000 mg...
Nexus Pharmaceuticals Receives FDA Approval for Isoproterenol Injection
Vernon Hills, Ill., August 3rd, 2017 – Nexus Pharmaceuticals announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Isoproterenol Hydrochloride Injection. Nexus...
Nexus Pharmaceuticals Receives FDA Approval for Sodium Nitroprusside Injection
Vernon Hills, Ill., May 31, 2017 – Nexus Pharmaceuticals announced today the immediate availability in the United States of Sodium Nitroprusside Injection. Nexus Pharmaceuticals’ Sodium Nitroprusside Injection is available as a single dose vial containing 50 mg per...
Get to know us
Learn about who we are and what we do
Lincolnshire, IL 60069 United States